Prelude Therapeutics (PRLD)
0.74
-0.02 (-2.50%)
At close: Mar 03, 2025, 12:26 PM
No 1D chart data available
| Bid | 0.73 |
| Market Cap | 40.78M |
| Revenue (ttm) | 4.66M |
| Net Income (ttm) | -95.42M |
| EPS (ttm) | -1.77 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -0.76 |
| Analyst | Buy |
| Ask | 0.75 |
| Volume | 55,468 |
| Avg. Volume (20D) | 422,039 |
| Open | 0.77 |
| Previous Close | 0.76 |
| Day's Range | 0.72 - 0.77 |
| 52-Week Range | 0.72 - 6.80 |
| Beta | 1.36 |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selecti...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 128
Stock Exchange NASDAQ
Ticker Symbol PRLD
Website https://www.preludetx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PRLD stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 507.29% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
